<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="273">
  <stage>Registered</stage>
  <submitdate>24/08/2005</submitdate>
  <approvaldate>26/08/2005</approvaldate>
  <actrnumber>ACTRN12605000223639</actrnumber>
  <trial_identification>
    <studytitle>The GABA Study</studytitle>
    <scientifictitle>Single-dose Pregabalin in Postoperative Pain Relief after Minor Gynaecological Surgery</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Prevention of Postoperative Pain</healthcondition>
    <conditioncode>
      <conditioncode1>Alternative and complementary medicine</conditioncode1>
      <conditioncode2>Pain management</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Surgery</conditioncode1>
      <conditioncode2>Other surgery</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Single-dose pregabalin 100 mg administered 1-2 hours pre-operatively, effect on postoperative pain assessed.</interventions>
    <comparator>Placebo </comparator>
    <control>Placebo</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Pain as assessed by visual analogue scale.</outcome>
      <timepoint>Immediately postoperatively and at 1, 2 and 24 hours. </timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Pain on movement and score for cramping pain also assessed.</outcome>
      <timepoint>Immediately postoperatively and at 1, 2 and 24 hours. </timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Total dose of fentanyl used intraoperatively and in recovery.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Total doses of other analgesics used postoperatively.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Presence of nausea or vomiting.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Presence of side effects of pregabalin:
headache, lightheadedness, drowsiness, ataxia, visual disturbance.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of Recovery score</outcome>
      <timepoint>At 2 and 24 hours postoperatively.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Modified Brief Pain Inventory Short Form</outcome>
      <timepoint>At 24 hours.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Health Outcome Recovery Survey</outcome>
      <timepoint>At 24 hours.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Undergoing minor gynaecological surgery on uterus/cervix without skin or mucosal incision, i.e. D&amp;C +/- Hysteroscopy. ASA 1 or 2.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Allergy to pregabalin.History of chronic pelvic pain.Receiving preoperative misoprostol.Currently taking opioids or other forms of pain relief, sedatives or anticonvulsants.Preoperative history of dizziness or severe headaches.Petient request for sedative/anxiolytic premedication.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Numbered containers of drug or placebo (identical capsules), randomised and prepared by pharmacy. Double blinded until all patients recruited and assessment finished.</concealment>
    <sequence>Computer generated randomisation schedule.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>8/08/2005</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>90</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Professor Michael Paech</primarysponsorname>
    <primarysponsoraddress>King Edward Memorial Hospital
374 Bagot Road
Subiaco
Perth WA 6008</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Pfizer Global Pharmaceuticals</fundingname>
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>Not applicable</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Women undergoing D&amp;C surgery often experience pain afterwards between 2 and 7 on a scale of 1-10. This pain is intially due to surgical trauma but may continue because of resulting inflammation. If the ongoing cycle of inflammation is reduced pain may be less. Pregabalin is a treatment for seizure disorders. It also has pain relieving and calming properties. It can reduce local tissue inflammation and the release of pain mediators. Therefore pregabalin given preoperatively may reduce postoperative pain.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>King Edward Memorial Hospital</ethicname>
      <ethicaddress>374 Bagot Road, Subiaco, Perth, WA  6008</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Professor Michael Paech</name>
      <address>King Edward Memorial Hospital
374 Bagot Road
Subiaco Perth WA 6008</address>
      <phone>+61 8 93402222 Pager 3223</phone>
      <fax>+61 8 93402260</fax>
      <email>Michael.Paech@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Professor Michael Paech or Research Nurses: Desiree Cavill &amp; Tracy Bingham</name>
      <address>King Edward Memorial Hospital
374 Bagot Road
Subiaco Perth WA 6008</address>
      <phone>+61 8 93402222 Pager 3223 (Mike Paech) or 3433 (Research Nurses)</phone>
      <fax>+61 8 93402260</fax>
      <email>Michael.Paech@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>